文献速递肝病消化道出血

重型COVID-19死亡患者中病毒感染周细胞促凝血表型与门静脉血栓及肺内血管扩张相关

Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19.
PubMed 文献 · J Hepatol · 2024-06-20

分析93例COVID-19死亡患者及17例对照,发现16/66例存在肺内血管扩张(IPVD),与较年轻年龄、较长病程、低氧血症加重及通气支持需求增加相关。IPVD患者门管区微血栓>82.5%,感染周细胞表达组织因子,体外实验示SARS-CoV-2感染周细胞上调TF并诱导内皮细胞高表达vWF。

要点

  • COVID-19死亡患者中IPVD见于16/66例,对照组未见。
  • IPVD组门管区微血栓>82.5%,周细胞壁增厚且表达TF。
  • 体外SARS-CoV-2感染周细胞上调TF,vWF处理促肺微血管内皮细胞成管。

核心结论

  • SARS-CoV-2感染肝周细胞引发局部促凝血反应,与广泛门管区微血栓、IPVD及致命性COVID-19呼吸衰竭加重相关。

研究设计与样本

  • 分析93例COVID-19死亡患者,17例COVID-19无关肺炎死亡者为对照;采用组织学、胸部CT、动脉血气及体外细胞实验。

主要发现

  • IPVD见于16/66例有肝肺组织学的COVID-19患者,对照组未见,胸部CT确认。
  • 与COVID-19/Non-IPVD相比,IPVD组年龄更轻(62 vs 78岁)、病程更长(25 vs 14天)、PaO2/FiO2从209降至89、通气支持需求更高(63% vs 22%)。
  • COVID-19/IPVD肝组织学示>82.5%门管区微血栓,αSMA/PDGFR-β+/SP+/NP+周细胞壁较Non-IPVD增厚。
  • 血栓性门小静脉与αSMA+面积相关,感染SP+/NP+周细胞表达TF;电镜见门管区周细胞病毒颗粒。
  • 体外SARS-CoV-2感染周细胞上调TF,诱导内皮细胞过表达vWF,vWF处理促人肺微血管内皮细胞成管扩展。

临床怎么用

  • 作者认为肝脏血管受累是COVID-19严重并发症,在长期且进行性加重的呼吸衰竭评估中应考虑,因其可能与IPVD发生相关。
  • 作者认为周细胞可能是血栓病理生理中被忽视的参与者,并可能成为新治疗靶点。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The underlying mechanisms and clinical impact of portal microthrombosis in severe COVID-19 are unknown. Intrapulmonary vascular dilation (IPVD)-related hypoxia has been described in severe liver diseases. We hypothesised that portal microthrombosis is associated with IPVD and fatal respiratory failure in COVID-19. METHODS: Ninety-three patients who died from COVID-19 were analysed for portal microvascular damage (histology), IPVD (histology and chest-computed tomography, CT), and hypoxemia (arterial blood gas). Seventeen patients who died from COVID-19-unrelated pneumonia served as controls. Vascular lesions and microthrombi were phenotyped for endothelial (vWF) and pericyte (αSMA/PDGFR-β) markers, tissue factor (TF), viral spike protein and nucleoprotein (SP, NP), fibrinogen, and platelets (CD41a). Viral particles in vascular cells were assessed by transmission electron microscopy. Cultured pericytes were infected with SARS-CoV-2 to measure TF expression and tubulisation of human pulmonary microvascular endothelial cells was assessed upon vWF treatment. RESULTS: IPVD was present in 16/66 patients with COVID-19, with available liver and lung histology, and was associated with younger age (62 vs. 78 years-old), longer illness (25 vs. 14 days), worsening hypoxemia (PaO2/FiO2 from 209 to 89), and an increased requirement for ventilatory support (63% vs. 22%) compared to COVID-19/Non-IPVD. IPVD, absent in controls, was confirmed by chest CT. COVID-19/IPVD liver histology showed portal microthrombosis in >82.5% of portal areas, with a thicker wall of αSMA/PDGFR-β+/SP+/NP+ pericytes compared with COVID-19/Non-IPVD. Thrombosed portal venules correlated with αSMA+ area, whereas infected SP+/NP+ pericytes expressed TF. SARS-CoV-2 viral particles were observed in portal pericytes. In vitro SARS-CoV-2 infection of pericytes upregulated TF and induced endothelial cells to overexpress vWF, which expanded human pulmonary microvascular endothelial cell tubules. CONCLUSIONS: SARS-CoV-2 infection of liver pericytes elicits a local procoagulant response associated with extensive portal microthrombosis, IPVD and worsening respiratory failure in fatal COVID-19. IMPACT AND IMPLICATIONS: Vascular involvement of the liver represents a serious complication of COVID-19 infection that must be considered in the work-up of patients with long-lasting and progressively worsening respiratory failure, as it may associate with the development of intrapulmonary vascular dilations. This clinical picture is associated with a procoagulant phenotype of portal venule pericytes, which is induced by SARS-CoV-2 infection of pericytes. Both observations provide a model that may apply, at least in part, to other vascular disorders of the liver, featuring obliterative portal venopathy, similarly characterised at the clinical level by development of hypoxemia and at the histological level by phlebosclerosis and reduced calibre of the portal vein branches in the absence of cirrhosis. Moreover, our findings shed light on an overlooked player in the pathophysiology of thrombosis, i.e. pericytes, which may present a novel therapeutic target.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Cadamuro M, Lasagni A, Radu CM, et al. Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19. J Hepatol. 2024. PMID: 38908437. doi:10.1016/j.jhep.2024.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。